Jason Scott Slakter, Chief Executive Officer at Ohr Pharmaceutical Inc (OHRP), bought 28,265 shares at $3.23 ($89K) on 2016-05-23, disclosed to the SEC on 2016-05-25.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.11 | 267 | $830 | 0.9% |
| 2 | $3.12 | 1,337 | $4K | 4.7% |
| 3 | $3.13 | 89 | $278 | 0.3% |
| 4 | $3.13 | 89 | $279 | 0.3% |
| 5 | $3.13 | 803 | $3K | 2.8% |
| 6 | $3.14 | 357 |
| $1K |
| 1.3% |
| 7 | $3.15 | 1,516 | $5K | 5.4% |
| 8 | $3.16 | 3,121 | $10K | 11.1% |
| 9 | $3.17 | 6,851 | $22K | 24.4% |
| 10 | $3.18 | 1,588 | $5K | 5.7% |
| 11 | $3.19 | 1,248 | $4K | 4.5% |
| 12 | $3.20 | 446 | $1K | 1.6% |
| 13 | $3.21 | 1,516 | $5K | 5.5% |
| 14 | $3.22 | 89 | $287 | 0.3% |
| 15 | $3.23 | 1,337 | $4K | 4.9% |
| 16 | $3.06 | 800 | $2K | 2.8% |
| 17 | $3.07 | 8 | $25 | 0.0% |
| 18 | $3.07 | 8 | $25 | 0.0% |
| 19 | $3.07 | 2,595 | $8K | 9.0% |
| 20 | $3.08 | 1,600 | $5K | 5.5% |
| 21 | $3.08 | 100 | $309 | 0.3% |
| 22 | $3.09 | 700 | $2K | 2.4% |
| 23 | $3.09 | 100 | $309 | 0.3% |
| 24 | $3.10 | 300 | $930 | 1.0% |
| 25 | $3.12 | 200 | $624 | 0.7% |
| 26 | $3.13 | 200 | $626 | 0.7% |
| 27 | $3.14 | 200 | $628 | 0.7% |
| 28 | $3.15 | 200 | $630 | 0.7% |
| 29 | $3.16 | 100 | $316 | 0.4% |
| 30 | $3.17 | 500 | $2K | 1.8% |
| Total | $3.15 avg | 28,265 | $89K | 100% |
| Filing → |
| OHRP | BUY | 2016-05-26 | $11K | — | Filing → |
| OHRP | BUY | 2016-04-12 | $21K | — | Filing → |
| OHRP | BUY | 2016-03-09 | $23K | — | Filing → |